BD Stock Down Despite Tie-Up to Boost Single-Cell Sequencing Workflow

Becton, Dickinson and Company (BDX) announced a multi-year collaboration with Opentrons Labworks to integrate robotic liquid-handling capabilities into BD’s single-cell multiomics instruments, aiming to automate critical experimental steps and accelerate disease research. This strategic partnership is designed to strengthen BD's Biosciences unit within the global sequencing market, which is projected to grow from $15.54 billion in 2023 to $62.48 billion by 2030. Despite the long-term growth potential, BDX shares declined by nearly 1.8% following the announcement and have underperformed significantly over the past year, losing 19.8%.

Analysis

Becton, Dickinson and Company (BDX) announced a multi-year collaboration with Opentrons to automate single-cell sequencing workflows, integrating the BD Rhapsody System with the Opentrons Flex platform. This partnership aims to strengthen BD's Biosciences (BDB) business unit by enabling hands-free multiomics experiments, accelerating disease research and drug development. The initiative targets the global sequencing market, projected to grow from $15.54 billion in 2023 to $62.48 billion by 2030 at a 22.2% CAGR.

Despite the strategic potential, BDX shares declined by nearly 1.8% following the announcement, reflecting a mixed immediate market reaction. This recent dip contributes to a significant underperformance over the past year, with the stock losing 19.8% against the industry's 2.7% gain and the S&P 500's 17.8% rise. However, BDX demonstrated a 7.6% earnings surprise in the last reported quarter and maintains an earnings yield of 7.8%, exceeding the industry average of 6.4%.

The collaboration is expected to enhance the cost-effectiveness and scalability of single-cell sequencing, aligning with the growing demand for gene therapy and consumer genomics. BD's BDB unit also reported strong Q3 FY25 performance, driven by the FACSDiscover A8 and robust reagent sales, indicating underlying operational strength. While the long-term benefits of this automation push are evident, the stock's current Zacks Rank #3 (Hold) suggests a cautious near-term outlook.

Key Decisions for Investors

• Investors should monitor the execution and commercial impact of the Opentrons collaboration on BD's BDB segment, given the significant projected growth in the global sequencing market.
• Despite the long-term strategic benefits, BDX's significant underperformance over the past year and immediate post-announcement stock decline warrant caution regarding near-term price action.
• Evaluate BDX's current valuation, including its 7.8% earnings yield, against its historical performance and the broader market, while considering its Zacks Rank #3 (Hold).
• Consider diversifying into other medical technology stocks with higher Zacks Ranks and stronger recent performance, such as Solventum, ResMed, or Masimo, as potential alternatives for growth.